Technologies

Our inventors have identified GAS5, an RNA-based biofluid marker for prediction and management of diabetes. GAS5 is a long non-coding RNA that has been found to have markedly reduced levels in serum from diabetic patients. Testing has demonstrated that GAS5 directly affects multiple insulin-responsive genes related to glucose metabolism and uptake. This study also establishes GAS5 as an circulating biomarker in blood, saliva and urine for early detection and diagnosis of prediabetes and in diabetes control. The invention is non-invasive and can be efficiently incorporated into standard care for diabetes.

Researchers at the University of South Florida have identified a non-invasive RNAbased biofluid marker that may be predictive of diabetes and long-term diabetic complications. This technology can be easily integrated into routine care to assess the risk of developing diabetes before the onset of diabetes.